(NASDAQ: NXTC) Nextcure's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Nextcure's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NXTC's revenue for 2026 to be $92,079,989, with the lowest NXTC revenue forecast at $92,079,989, and the highest NXTC revenue forecast at $92,079,989. On average, 1 Wall Street analysts forecast NXTC's revenue for 2027 to be $195,321,189, with the lowest NXTC revenue forecast at $195,321,189, and the highest NXTC revenue forecast at $195,321,189.
In 2028, NXTC is forecast to generate $1,130,072,594 in revenue, with the lowest revenue forecast at $1,130,072,594 and the highest revenue forecast at $1,130,072,594.